Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Bitfarms Ltd. regarding a class action lawsuit due to alleged misleading financial statements and internal control deficiencies [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Bitfarms issued materially false and misleading statements during the class period from March 21, 2023, to December 9, 2024 [3]. - Specific allegations include: - Deficient internal controls over financial reporting [3]. - Incorrect categorization of proceeds from the sale of digital assets as cash flow from operating activities instead of investing activities [3]. - Overstatement of the remediation of material weaknesses in internal controls related to the classification of 2021 Warrants [3]. - Misstatements in previously issued financial statements, which may require restatement [3]. - Public statements made by the company were materially false and misleading throughout the relevant period [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 8, 2025, to participate in potential recovery [4]. - Registration includes enrollment in a portfolio monitoring software for status updates on the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fortrea Holdings Inc. regarding a class action lawsuit due to alleged misleading statements and overestimations related to the company's financial projections and business model [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from July 3, 2023, to February 28, 2025 [3]. - Allegations include that Fortrea overestimated revenue contributions from long-term projects, overstated cost savings from exiting transition services agreements, and inflated EBITDA targets for 2025 [3]. Allegations Breakdown - Fortrea allegedly overestimated the revenue from its Pre-Spin Projects for 2025 [3]. - The company is accused of overstating potential cost savings from exiting certain agreements [3]. - As a result, the company's previously announced EBITDA targets for 2025 were inflated [3]. - The viability of Fortrea's post-spin-off business model and its financial prospects were also allegedly overstated [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 1, 2025, to participate in potential recovery [4]. - Registered shareholders will receive updates through a portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Group 1: Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS [3]. - Specific allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to a halt in trials and increased regulatory scrutiny [3]. Group 2: Shareholder Actions - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline of August 25, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [5].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors regarding the monitoring of cost trends related to the Medicaid "redetermination" process and assured that premium rates were sufficient to cover rising costs [4]. - It was revealed that the redetermination process led to a significant increase in the utilization of Medicaid members, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 earnings, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, and lowered EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [7]. - Following this announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [8].

Core Points - President Trump claims his settlement with Paramount Global is valued at over $32 million, which is more than double the company's stated figure of $16 million [1][3][4] - The settlement includes a side deal for public service announcements (PSAs) valued between $15 million and $20 million, promoting causes supported by Trump [2][15] - Paramount has denied any connection between the settlement and the pending $8 billion merger with Skydance Media, asserting that the settlement does not include PSAs [8][4] Company Details - The settlement covers payments for Trump's future presidential library and legal fees, with "60 Minutes" agreeing to release interview transcripts after airing [7][10] - Paramount's initial offer was $15 million, which was later negotiated down from Trump's original demand of $100 million to around $50 million [11] - High-level negotiations included pressure from Paramount's controlling shareholder, Shari Redstone, to settle the dispute to avoid potential legal costs [13][14]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged misrepresentations regarding the safety risks of its product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Sarepta and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 25, 2025, with the option to remain as absent class members if they choose not to take action [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Points - Paramount settled with President Trump for $16 million over alleged edits in "60 Minutes" that Trump claimed favored Kamala Harris, leading to media criticism [2] - The settlement funds are intended to cover Trump's legal fees and contribute to his Presidential Library, similar to previous settlements with other media companies [3] - The IRS may view settlement payments for legal fees as taxable income, depending on whether the fees were previously deducted [5][6] Tax Implications - Settling lawsuits with funds directed to charity may not always provide a complete tax solution, as the IRS may treat it as a payment to the plaintiff first [4][7] - Legal settlements are generally taxable based on the origin of the claim, with specific rules and exceptions that can complicate tax obligations [8] - Mental anguish claims, such as those made by Trump regarding the "60 Minutes" edits, do not qualify for tax exclusions under current IRS rules [10] Legal Fees and Taxation - Legal fees can complicate tax situations, as plaintiffs are treated as receiving the full settlement amount for tax purposes, regardless of how much is paid to their attorney [12][13] - Punitive damages and interest from settlements are always taxable, which can affect the overall tax liability of the plaintiff [14]

LOS ANGELES, July 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against 3D Systems Corporation ("3D Systems" or "the Company") (NYSE: DDD) for violations of securities laws.Shareholders who purchased the Company's securities between August 13, 2024 and May 13, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 12, 2025.CASE DETAILS: The Complaint claims that the Company made false and misleading statements to the market. 3D Systems ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price after the FDA placed a clinical hold on the study following a Serious Adverse Event [2][3]. Group 1: Allegations and Events - The lawsuit claims that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths [2]. - The company amended the clinical trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a patient's death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Group 2: Shareholder Actions - Shareholders who purchased RCKT shares during the class period from February 27, 2025, to May 26, 2025, are encouraged to register for the class action and may seek lead plaintiff status by the deadline of August 11, 2025 [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [3]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Vestis Corporation regarding a class action lawsuit due to allegations of misleading statements and failure to meet growth expectations, resulting in a significant stock price decline [1][2]. Group 1: Allegations and Financial Impact - The class period for the allegations against Vestis Corporation is from May 2, 2024, to May 6, 2025 [2]. - The complaint states that Vestis provided overly positive statements while concealing material adverse facts about its business growth capabilities, particularly regarding customer experience and retention [2]. - Following the announcement of disappointing financial results for Q2 fiscal 2025 and the withdrawal of revenue guidance, Vestis' stock price plummeted from $8.71 to $5.44, a decline of approximately 37.54% in one day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by August 8, 2025, to potentially become lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4].